We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal
Read MoreHide Full Article
Key Takeaways
Eli Lilly agreed to acquire Orna Therapeutics in a $2.4B deal with milestone-based payments.
LLY will gain an in vivo CAR-T pipeline, including ORN-252, for B-cell-driven autoimmune diseases.
Eli Lilly will also acquire Orna's circular RNA platform to support pipeline diversification.
Eli Lilly (LLY - Free Report) announced that it entered a definitive agreement to acquire the privately held clinical-stage biotech Orna Therapeutics in a deal valued at $2.4 billion. This transaction includes both upfront consideration and milestone-based payments, though the company did not provide a detailed financial breakdown.
Following this acquisition, Eli Lilly will acquire a broad portfolio of in vivo CAR-T pipeline, including Orna’s lead asset, ORN-252, designed to address B-cell-driven autoimmune diseases. Unlike ex-vivo therapies, where cells are removed, modified and then inserted back into one’s body, in vivo therapies involve infusing new genes directly into the body.
Alongside pipeline assets, Eli Lilly will acquire Orna Therapeutics’ proprietary platforms, including its circular RNA platform, which is designed to enable therapeutic applications that may not be feasible with existing RNA or conventional cell-therapy technologies.
Orna Therapeutics has previously attracted interest from large pharmaceutical companies for its platform technologies. It has entered collaborations with Merck (MRK - Free Report) to develop next-generation gene-editing therapies and with Vertex Pharmaceuticals (VRTX - Free Report) to work on next-generation vaccine candidates.
Eli Lilly’s Stock Movement
As seen in the chart below, Eli Lilly’s shares have outperformed the industry in the past year.
Image Source: Zacks Investment Research
How Does This Buyout Benefit LLY?
This acquisition comes at a time when Lilly’s financial performance remains strong, supported by the blockbuster success of its GLP-1 therapies Mounjaro (for diabetes) and Zepbound (for obesity). This momentum has helped make Eli Lilly the first pharmaceutical company to reach a market capitalization of $1 trillion.
Rather than addressing near-term revenue pressure, the Orna deal appears aimed at long-term pipeline diversification. Recent regulatory approvals across multiple therapeutic areas — immunology (Omvoh and Ebglyss), oncology (Jaypirca) and neuroscience (Kisunla) —highlight Eli Lilly’s intent to diversify beyond metabolic diseases. A potential deal for Orna Therapeutics fits this trend.
The transaction also benefits Orna, which lacks the commercial infrastructure and global scale required to bring advanced therapies to market, areas where LLY is already well established.
This is the second acquisition deal signed by Lilly so far this year. The company opened its 2026 M&A activity last month when it offered to buy Ventyx Biosciences for $1.2 billion. Through this deal, Eli Lilly intends to deepen its exposure in oral small-molecule therapies targeting inflammatory-mediated diseases, where there is a high unmet need. The deal will add Ventyx’s differentiated portfolio of clinical-stage oral therapies, particularly NLRP3 inhibitors, being developed across cardiometabolic, neurodegenerative and autoimmune indications. This transaction is expected to close in the first half of 2026.
View the Zacks #1 Rank List
Image: Bigstock
LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal
Key Takeaways
Eli Lilly (LLY - Free Report) announced that it entered a definitive agreement to acquire the privately held clinical-stage biotech Orna Therapeutics in a deal valued at $2.4 billion. This transaction includes both upfront consideration and milestone-based payments, though the company did not provide a detailed financial breakdown.
Following this acquisition, Eli Lilly will acquire a broad portfolio of in vivo CAR-T pipeline, including Orna’s lead asset, ORN-252, designed to address B-cell-driven autoimmune diseases. Unlike ex-vivo therapies, where cells are removed, modified and then inserted back into one’s body, in vivo therapies involve infusing new genes directly into the body.
Alongside pipeline assets, Eli Lilly will acquire Orna Therapeutics’ proprietary platforms, including its circular RNA platform, which is designed to enable therapeutic applications that may not be feasible with existing RNA or conventional cell-therapy technologies.
Orna Therapeutics has previously attracted interest from large pharmaceutical companies for its platform technologies. It has entered collaborations with Merck (MRK - Free Report) to develop next-generation gene-editing therapies and with Vertex Pharmaceuticals (VRTX - Free Report) to work on next-generation vaccine candidates.
Eli Lilly’s Stock Movement
As seen in the chart below, Eli Lilly’s shares have outperformed the industry in the past year.
Image Source: Zacks Investment Research
How Does This Buyout Benefit LLY?
This acquisition comes at a time when Lilly’s financial performance remains strong, supported by the blockbuster success of its GLP-1 therapies Mounjaro (for diabetes) and Zepbound (for obesity). This momentum has helped make Eli Lilly the first pharmaceutical company to reach a market capitalization of $1 trillion.
Rather than addressing near-term revenue pressure, the Orna deal appears aimed at long-term pipeline diversification. Recent regulatory approvals across multiple therapeutic areas — immunology (Omvoh and Ebglyss), oncology (Jaypirca) and neuroscience (Kisunla) —highlight Eli Lilly’s intent to diversify beyond metabolic diseases. A potential deal for Orna Therapeutics fits this trend.
The transaction also benefits Orna, which lacks the commercial infrastructure and global scale required to bring advanced therapies to market, areas where LLY is already well established.
This is the second acquisition deal signed by Lilly so far this year. The company opened its 2026 M&A activity last month when it offered to buy Ventyx Biosciences for $1.2 billion. Through this deal, Eli Lilly intends to deepen its exposure in oral small-molecule therapies targeting inflammatory-mediated diseases, where there is a high unmet need. The deal will add Ventyx’s differentiated portfolio of clinical-stage oral therapies, particularly NLRP3 inhibitors, being developed across cardiometabolic, neurodegenerative and autoimmune indications. This transaction is expected to close in the first half of 2026.
Eli Lilly and Company Price
Eli Lilly and Company price | Eli Lilly and Company Quote
LLY’s Zacks Rank
Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.